A rising hedge fund star thinks that MannKind is so over-hyped that the health-care company's stock will fall 90 percent.» Read More
Shares of Facebook hit a record high after a surge in mobile advertising revenue helped the world's No. 1 social network trounce analysts' estimates.
Tim Seymour provides a look behind his trade on Starbucks ahead of quarterly earnings.
Investors are starting to score from some S&P 500 stocks springing back from a long period of suffering. USA Today reports.
Flash manufacturing data came in mostly stronger than expected, but a mixed report from Caterpillar tempered hopes.
Apple could be "obsolete" in three years, due to increasing competition in the technology sector, one analyst told CNBC.
Cramer often says that if you do homework, you can prosper by holding a relatively small number of stocks.
Some of the names on the move ahead of the open.
Customers love their food. But the CFO says there's little appetite for a stock split.
The "Fast Money" traders share their final trades of the day.
An influx of crowdfunding options provides new ways for needy students to sidestep traditional lenders.
CNBC's Bob Pisani explains why emerging market economies are turning around and growing more aggressively again, despite a lack of evidence to support a rally.
When shares tumble sharply in a single session, you can be sure Jim Cramer wants to know what’s going on.
Even with this week's weakness, Amazon.com stock has been outperforming rival retailers though it will likely face a fairly volatile trading day after it reports.
Though Apple posted profits that beat expectations, investor Roger McNamee found reason to throw cold water on the tech giant.
Microsoft and Cisco may sound old school compared to internet high fliers, but some of the old timers are at levels not seen since the dot com bubble.
Marc Faber, famed for his gloomy financial market views, took some time instead to highlight areas of the market that he actually liked.
Technology firms led market gains as the S&P Tech sector hit its highest level since November 2000 and the Nasdaq 100 reached a 14-year high.
Someone bet big in the options market that Puma Biotechnology would be a winner in the days before a positive drug trial sent its stock soaring.
Geopolitical shocks are affecting gold prices. If you want to invest in the safe-haven metal, you have a range of options to choose from.
Results of a clinical trial of a breast cancer drug could make this company a takeover target, too, says CNBC's Jim Cramer.
Get the best of CNBC in your inbox